Cargando…

Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations

Evidence has suggested survival benefits of maintenance for advanced NSCLC patients not progressing after first‐line chemotherapy. Additionally, particular first‐line targeted therapies have shown survival improvements in selected populations. Optimal first‐line and maintenance therapies remain uncl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Pui San, Bilger, Marcel, de Lima Lopes, Gilberto, Acharyya, Sanchalika, Haaland, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548880/ https://www.ncbi.nlm.nih.gov/pubmed/28675660 http://dx.doi.org/10.1002/cam4.1101

Ejemplares similares

Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
por: Haaland, Benjamin, et al.
Publicado: (2014)

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
por: Haaland, Benjamin, et al.
Publicado: (2014)

A systematic review and network meta‐analysis of immunotherapy and targeted therapy for advanced melanoma
por: da Silveira Nogueira Lima, Joao Paulo, et al.
Publicado: (2017)

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
por: Besse, Benjamin, et al.
Publicado: (2015)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
por: Wan, Ning, et al.
Publicado: (2020)

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
por: Ridouane, Yassine, et al.
Publicado: (2017)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines
por: Hu, Kevin, et al.
Publicado: (2021)

Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC
por: Ni, Xiang, et al.
Publicado: (2015)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
por: Tan, Pui S, et al.
Publicado: (2014)

Cellular Therapy in NSCLC: Between Myth and Reality
por: Imbimbo, Martina, et al.
Publicado: (2023)

How has the coronavirus pandemic impacted chemoradiotherapy for stage 3 non-small cell lung cancer (NSCLC) in our centre?
por: Kathirgamakarthigeyan, Sangary, et al.
Publicado: (2022)

Implications of ubiquitination and the maintenance of replication fork stability in cancer therapy
por: Xia, Donghui, et al.
Publicado: (2023)

First-line ICIs in renal cell carcinoma
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC
por: Arnett, Andrea L.H., et al.
Publicado: (2019)

CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line
por: Asai, Ryoma, et al.
Publicado: (2019)

The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen
por: Geng, Nan, et al.
Publicado: (2021)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
por: Shen, Lan, et al.
Publicado: (2020)

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials
por: Li, Lee X, et al.
Publicado: (2023)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab
por: Shang, Xiaoling, et al.
Publicado: (2021)

Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS)
por: Abraham, Christopher, et al.
Publicado: (2017)

Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
por: Babu, K. Govind, et al.
Publicado: (2019)

Innovative dual‐function protective scope mask and filtration system for aerosol generating ENT scope procedures
por: Chew, Hui Sing, et al.
Publicado: (2022)

Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A population‐based cohort study
por: Tan, Pui San, et al.
Publicado: (2020)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
por: Cortellini, Alessio, et al.
Publicado: (2020)

Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014
por: Junior, Gilberto de Lima Lopes
Publicado: (2014)

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials
por: Shao, Fengping, et al.
Publicado: (2020)

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients
por: Emprou, Camille, et al.
Publicado: (2018)

A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
por: Qiao, Nan, et al.
Publicado: (2021)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
por: Chan, Wing-Lok, et al.
Publicado: (2014)

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
por: Qin, Boyu, et al.
Publicado: (2021)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Dechow, Tobias, et al.
Publicado: (2021)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lnt5tou7akcvk84j78grg9tkeo